ACRO Biomedical Co., Ltd. (6748.TWO)
TWD 25.7
(-2.1%)
TWD 25.7
(-2.1%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -48.26 Million | -45.15 Million | -47.82 Million | -31.32 Million | - |
| Net Income | -41.41 Million | -60.88 Million | -50.77 Million | -50.01 Million | - |
| Depreciation & Amortization | 10.97 Million | 9.21 Million | 9.5 Million | 12.53 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | 743 Thousand | 1.38 Million | 3.64 Million | - |
| Change in working capital | 1.85 Million | 2.27 Million | -6.66 Million | 2.28 Million | - |
| Other non-cash items | -22.31 Million | 3.38 Million | 298 Thousand | 121 Thousand | - |
| Investing Cash Flow | -33.59 Million | -10.54 Million | 36.85 Million | -74.68 Million | - |
| Investments in PPE | -22.46 Million | -4.43 Million | -3.3 Million | -3.83 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -10.59 Million | -4.09 Million | - | -71.11 Million | - |
| Sales/Maturities of investments | - | - | 40.2 Million | - | - |
| Other Investing Activities | -535 Thousand | -2 Million | -48 Thousand | 262 Thousand | - |
| Financing Cash Flow | 345.27 Million | 304.4 Million | -3.42 Million | 96.88 Million | - |
| Debt repayment | -679 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 350 Million | 307.85 Million | - | 100 Million | - |
| Other Financing Activities | -4.72 Million | - | - | - | - |
| Accounts receivables | -1.1 Million | - | - | - | - |
| Accounts payables | 89 Thousand | - | - | - | - |
| Inventory | 2.9 Million | -1.95 Million | -1.69 Million | 1.6 Million | - |
| Other working capital | 53 Thousand | - | - | - | - |
| Cash at beginning of period | 281.84 Million | 32.26 Million | 45.65 Million | 55.45 Million | - |
| Cash at end of period | 544.16 Million | 281.84 Million | 32.26 Million | 45.65 Million | - |
| Capital Expenditure | -22.46 Million | -4.43 Million | -3.3 Million | -3.83 Million | - |
| Effect of forex changes on cash | -1.1 Million | 880 Thousand | 996 Thousand | -670 Thousand | - |
| Net cash flow / Change in cash | 262.31 Million | 249.58 Million | -13.39 Million | -9.8 Million | - |
| Free Cash Flow | -70.73 Million | -49.59 Million | -51.13 Million | -35.16 Million | - |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 Q4 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -26.35 Million | -9.9 Million | -41.41 Million | -31.51 Million | -34.39 Million | -60.88 Million |
| Depreciation & Amortization | 6.09 Million | 5.81 Million | 10.97 Million | 5.16 Million | 4.68 Million | 9.21 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | 743 Thousand |
| Change in working capital | -2.29 Million | 3.03 Million | 1.85 Million | -499 Thousand | 2.79 Million | 2.27 Million |
| Other non-cash items | -1.17 Million | -21.77 Million | -22.31 Million | 2.09 Million | 2.36 Million | 3.38 Million |
| Investing Cash Flow | -13.61 Million | -24.5 Million | -33.59 Million | -9.09 Million | -3.3 Million | -10.54 Million |
| Investments in PPE | -20.05 Million | -12.56 Million | -22.46 Million | -8.43 Million | -2.15 Million | -4.43 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -10.59 Million | -10.59 Million | - | -337 Thousand | -4.09 Million |
| Sales/Maturities of investments | 7.86 Million | -30 Thousand | - | 30 Thousand | 200 Thousand | - |
| Other Investing Activities | 35 Thousand | -150 Thousand | -535 Thousand | -385 Thousand | -453 Thousand | -2 Million |
| Financing Cash Flow | -2.84 Million | 347.05 Million | 345.27 Million | -2.45 Million | -898 Thousand | 304.4 Million |
| Debt repayment | -227 Thousand | -398 Thousand | - | -281 Thousand | -859 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 350 Million | 350 Million | - | - | 307.85 Million |
| Other Financing Activities | -2.61 Million | -2.54 Million | - | -2.17 Million | -1.75 Million | - |
| Accounts receivables | 741 Thousand | 169 Thousand | - | -1.26 Million | -5.17 Million | - |
| Accounts payables | 667 Thousand | 145 Thousand | - | -56 Thousand | 128 Thousand | - |
| Inventory | -314 Thousand | 1.43 Million | 2.9 Million | 1.47 Million | -142 Thousand | -1.95 Million |
| Other working capital | -3.38 Million | 1.28 Million | - | -646 Thousand | 7.97 Million | - |
| Cash at beginning of period | 544.16 Million | 245.58 Million | 281.84 Million | 281.84 Million | 310.32 Million | 32.26 Million |
| Cash at end of period | 504.72 Million | 544.16 Million | 544.16 Million | 245.58 Million | 281.84 Million | 281.84 Million |
| Capital Expenditure | -20.05 Million | -12.56 Million | -22.46 Million | -8.43 Million | -2.15 Million | -4.43 Million |
| Effect of forex changes on cash | - | - | -1.1 Million | - | - | 880 Thousand |
| Net cash flow / Change in cash | -39.43 Million | 298.57 Million | 262.31 Million | -36.26 Million | -28.48 Million | 249.58 Million |
| Free Cash Flow | -43.77 Million | -35.4 Million | -70.73 Million | -33.18 Million | -26.71 Million | -49.59 Million |
NVP8
SPANDANA
ROG
3571
PBL
003200